New hope for bile duct cancer: targeted drug shows promise in early trial
NCT ID NCT06178588
First seen Feb 24, 2026 · Last updated May 15, 2026 · Updated 11 times
Summary
This study tests a drug called sacituzumab govitecan in 15 people with advanced bile duct cancer that has spread or come back. The drug works like a smart bomb, attaching to a protein on cancer cells and delivering a toxic payload to kill them. The main goal is to see how many patients' tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Kansas Cancer Center
Kansas City, Kansas, 66160, United States
Conditions
Explore the condition pages connected to this study.